Compare Heron Therapeutics Inc (HRTX) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Oatly Group AB - ADR — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Oatly Group AB - ADR trades at $9.46 (market cap $308.50M). The key difference: Oatly Group AB - ADR is far larger — about 3.4× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| HRTX | OTLY | |
|---|---|---|
Market Cap | $91.46M | $308.50M |
Sector | Health | Consumer Staples |
52-Week High | $1.96 | $18.54 |
52-Week Low | $0.39 | $8.03 |
Enterprise Value | $189.36M | $806.12M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
OTLY trades at $9.81, down 2.29% on the day, with a bullish technical signal from moving averages. Revenue grew to $862.46M in 2025, but net losses persist at -$152.77M. Cash burn remains a concern with negative operating cash flow of -$23.72M. The company announced Q2 2026 results for July 22, 2026, and continues brand partnerships like the Nespresso iced coffee collaboration.
Outlook is mixed: strong brand and revenue growth offer potential, but profitability challenges and high debt-to-asset ratio of 66.53% pose significant risks. Analyst consensus is divided with 44% buy ratings, yet cash runway constraints highlighted by Seeking Alpha on 2026-05-14 require careful monitoring for equity investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
